| Original language | English |
|---|---|
| Pages (from-to) | 4883-4897 |
| Number of pages | 15 |
| Journal | Clinical Cancer Research |
| Volume | 27 |
| Issue number | 17 |
| Early online date | 24 Jun 2021 |
| DOIs | |
| Publication status | Published - 1 Sept 2021 |
Bibliographical note
Funding Information:We thank the Translational Breast Cancer Research Consortium and its three foundation partners (The AVON Foundation, The Breast Cancer Research Foundation, and Susan G. Komen for the Cure), and we are grateful for all the patients and investigators who participated in TBCRC009. Funding was provided by the NCI-AVON Partners for Progress Award 3P30CA06516-45S2 (S.J. Isakoff), and by the Tracey Davis Memorial Fund, Rosanne’s Rush for Research, the Boston Chapter of Golfers Against Cancer, and the MGH Executive Committee on Research (ECOR) Research Scholar Award (L.W. Ellisen), and the National Cancer Center, the MGH ECOR Fund for Medical Discovery, and the MGH Cancer Center Excellence Award (S.-B. Koh).
Funding Information:
S.-B. Koh has a patent for RASAL2 biomarker pending. S.J. Isakoff reports grants from Translational Breast Cancer Research Consortium during the conduct of the study, as well as personal fees from Mylan, Myriad, OncoPep, Puma, Seattle Genetics, and Novartis; grants and personal fees from AbbVie; and grants from AstraZeneca and Merck outside the submitted work. E.L. Mayer reports other support from Lilly, Novartis, and Pfizer outside the submitted work. T.A. Traina reports other support from TBCRC during the conduct of the study, as well as grants, personal fees, and nonfinancial support from Roche, Astellas, Ayala, Daiichi Sankyo, and Gilead and
Funding Information:
We thank the Translational Breast Cancer Research Consortium and its three foundation partners (The AVON Foundation, The Breast Cancer Research Foundation, and Susan G. Komen for the Cure), and we are grateful for all the patients and investigators who participated in TBCRC009. Funding was provided by the NCIAVON Partners for Progress Award 3P30CA06516-45S2 (S.J. Isakoff), and by the Tracey Davis Memorial Fund, Rosanne's Rush for Research, the Boston Chapter of Golfers Against Cancer, and the MGH Executive Committee on Research (ECOR) Research Scholar Award (L.W. Ellisen), and the National Cancer Center, the MGH ECOR Fund for Medical Discovery, and the MGH Cancer Center Excellence Award (S.-B. Koh).
Funding Information:
personal fees from Pfizer, Merck, AstraZeneca, and SeaGen outside the submitted work. L.A. Carey reports grants from NIH and Bristol Myers Squibb during the conduct of the study. H.S. Rugo reports grants from Pfizer, Merck, Novartis, Lilly, Roche, Odonate, Daiichi, Seattle Genetics, Macrogenics, Sermonix, Boehringer Ingelheim, Polyphor, AstraZeneca, and Immunomedics and personal fees from Puma, Mylan, and Samsung during the conduct of the study. M.C. Liu reports other support from Eisai, Genentech, Merck, Novartis, Seattle Genetics, Tesaro, AstraZeneca, Pfizer, and Genomic Health outside the submitted work. V. Stearns reports grants from Biocept, Pfizer, Novartis, Medimmune, and Puma Biotechnology outside the submitted work and is a member, Data Safety Monitoring Board, Immunomedics, Inc. S. Ramaswamy reports grants from NIH during the conduct of the study. L.W. Ellisen reports grants from NIH, NCI, National Cancer Center, and MGH ECOR and non-financial support from AVON Foundation, BCRF, and Susan G. Komen Foundation during the conduct of the study; in addition, L.W. Ellisen has a patent for RASAL2 biomarker pending. No disclosures were reported by the other authors.
Publisher Copyright:
© 2021 American Association for Cancer Research.
Access to Document
- Full-text PDF (final published version)
This is the final published version of the article (version of record). It first appeared online via AACR at https://doi.org/10.1158/1078-0432.CCR-21-0714 . Please refer to any applicable terms of use of the publisher.